Age-Related Macular Degeneration: Epidemiology Forecast to 2034

Age-related macular degeneration (AMD) is a chronic, progressive ophthalmological condition characterized by the gradual degeneration of the macula, the specialized area of the retina responsible for high-acuity central vision. It is recognized as the predominant cause of significant and irreversible vision loss among the older demographic. AMD is clinically staged as early, intermediate, and late. Late AMD, representing the advanced phase of the disease, is further subcategorized into late dry AMD (geographic atrophy) and wet AMD (neovascular AMD) (National Eye Institution, 2021). A meta-analysis indicated a pooled prevalence of 8.69% for any AMD in adults ages 45-85 years. However, country-specific prevalence can reach 30-40%. Beyond its high prevalence, AMD is linked to severe disability, significantly impacting the quality of life and emotional well-being of affected individuals (Augood et al., 2006; Hassell, 2006; Wong et al., 2014).

In 2024, there were 13,788,126 diagnosed incident cases of AMD in men and women combined, ages 50 years and older, in the 7MM. The US accounted for the majority of these cases with 3,378,351 diagnosed incident cases, while Germany accounted for the fewest cases with 1,160,172 cases in 2024. The analyst epidemiologists forecast an increase in the diagnosed incident cases of AMD to 15,349,696 cases in 2034 in the 7MM at an annual growth rate (AGR) of 1.13% during the forecast period.

In 2024, there were 93,262,936 total prevalent cases of AMD in men and women combined, ages 50 years and older, in the 7MM. The US accounted for the majority of these cases with 23,514,756 total prevalent cases, while Germany accounted for the fewest cases with 7,799,623 cases in 2024. The analyst epidemiologists forecast an increase in the total prevalent cases of AMD to 103,016,570 cases in 2034 in the 7MM at an AGR of 1.05% during the forecast period.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report provides a 10-year epidemiological forecast of the diagnosed incident cases (newly diagnosed patients), total prevalent cases (including both diagnosed and undiagnosed), and diagnosed prevalent cases of AMD. In this analysis, AMD cases are segmented into early AMD and late AMD, with late AMD further segmented into late dry AMD and wet AMD subtypes.
In this report, each segment is broken down by sex and age (50-59 years, 60-69 years, 70-79 years, and 80 years and older). The total prevalent cases and diagnosed prevalent cases of late dry AMD and wet AMD were segmented for both sexes and ages 50 years and older.
The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. Additionally, in cases of data scarcity, The analyst epidemiologists used primary market research (PMR) data wherever necessary.

Reasons to Buy

The Age-related macular degeneration (AMD) epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global AMD market.
Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.

1 Age-Related Macular Degeneration: Executive Summary

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2 Epidemiology

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 7MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Forecast assumptions and methods: diagnosed incident cases of AMD
2.4.4 Forecast assumptions and methods: total prevalent cases of AMD
2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
2.5 Epidemiological forecast for AMD (2024-34)
2.5.1 Diagnosed incident cases of AMD
2.5.2 Age-specific diagnosed incident cases of AMD
2.5.3 Sex-specific diagnosed incident cases of AMD
2.5.4 Diagnosed incident cases of early AMD
2.5.5 Diagnosed incident cases of late AMD
2.5.6 Diagnosed incident cases of late dry AMD
2.5.7 Diagnosed incident cases of wet AMD
2.5.8 Total prevalent cases of AMD
2.5.9 Age-specific total prevalent cases of AMD
2.5.10 Sex-specific total prevalent cases of AMD
2.5.11 Total prevalent cases of early AMD
2.5.12 Total prevalent cases of late AMD
2.5.13 Total prevalent cases of late dry AMD
2.5.14 Total prevalent cases of wet AMD
2.5.15 Diagnosed prevalent cases of AMD
2.5.16 Age-specific diagnosed prevalent cases of AMD
2.5.17 Sex-specific diagnosed prevalent cases of AMD
2.5.18 Diagnosed prevalent cases of early AMD
2.5.19 Diagnosed prevalent cases of late AMD
2.5.20 Diagnosed prevalent cases of late dry AMD
2.5.21 Diagnosed prevalent cases of wet AMD
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 Limitations of the analysis
2.6.3 Strengths of the analysis

3 Appendix

3.1 Bibliography
3.2 Primary research - prescriber survey
3.3 About the authors
3.3.1 Epidemiologist
3.3.2 Reviewers
3.3.3 Vice President of Disease Intelligence and Epidemiology
3.3.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About the Analyst

List of Tables

Table 1: Summary of changes to data types and countries
Table 2: Summary of updated data types
Table 3: Risk factors and comorbid conditions associated with AMD
Table 4: High-prescribing physicians (KOL and non-KOLs) surveyed, by country

List of Figures

Figure 1: 7MM, diagnosed incident cases of AMD, both sexes, N, ages =50 years, 2024 and 2034
Figure 2: 7MM, total prevalent cases of AMD, both sexes, N, ages =50 years, 2024 and 2034
Figure 3: 7MM, diagnosed prevalent cases of AMD, both sexes, N, ages =50 years, 2024 and 2034
Figure 4: 7MM, diagnosed incidence of AMD, both sexes, ages =50 years, cases per 100,000 population, 2024
Figure 5: 7MM, total prevalence of AMD, both sexes, ages =50 years, %, 2024
Figure 6: 7MM, diagnosed prevalence of AMD, both sexes, ages =50 years, 2024
Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
Figure 8: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
Figure 10: 7MM, diagnosed incident cases of AMD, N, both sexes, ages =50 years, 2024
Figure 11: 7MM, age-specific diagnosed incident cases of AMD, both sexes, N, ages =50 years, 2024
Figure 12: 7MM, sex-specific diagnosed incident cases of AMD, N, ages =50 years, 2024
Figure 13: 7MM, diagnosed incident cases of early AMD, N, both sexes, ages =50 years, 2024
Figure 14: 7MM, diagnosed incident cases of late AMD, N, both sexes, ages =50 years, 2024
Figure 15: 7MM, diagnosed incident cases of late dry AMD, N, both sexes, ages =50 years, 2024
Figure 16: 7MM, diagnosed incident cases of wet AMD, N, both sexes, ages =50 years, 2024
Figure 17: 7MM, total prevalent cases of AMD, both sexes, ages =50 years, N, 2024
Figure 18: 7MM, age-specific total prevalent cases of AMD, both sexes, N, ages =50 years, 2024
Figure 19: 7MM, sex-specific total prevalent cases of AMD, N, ages =50 years, 2024
Figure 20: 7MM, total prevalent cases of early AMD, both sexes, ages =50 years, N, 2024
Figure 21: 7MM, total prevalent cases of late AMD, both sexes, ages =50 years, N, 2024
Figure 22: 7MM, total prevalent cases of late dry AMD, both sexes, ages =50 years, N, 2024
Figure 23: 7MM, total prevalent cases of wet AMD, both sexes, ages =50 years, N, 2024
Figure 24: 7MM, diagnosed prevalent cases of AMD, both sexes, ages =50 years, N, 2024
Figure 25: 7MM, age-specific diagnosed prevalent cases of AMD, both sexes, N, ages =50 years, 2024
Figure 26: 7MM, sex-specific diagnosed prevalent cases of AMD, N, ages =50 years, 2024
Figure 27: 7MM, diagnosed prevalent cases of early AMD, both sexes, ages =50 years, N, 2024
Figure 28: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages =50 years, N, 2024
Figure 29: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages =50 years, N, 2024
Figure 30: 7MM, diagnosed prevalent cases of wet AMD, both sexes, ages =50 years, N, 2024

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5341EUR$5,995USD£4,647GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€10681EUR$11,990USD£9,294GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16022EUR$17,985USD£13,941GBP

Scope

Reasons to Buy

Table of Contents

Related Topics

Related Reports

Dry Age-Related Macular Degeneration - Epidemiology Forecast - 2034

Intermediate AMD - Epidemiology Forecast - 2034

Glaucoma: Seven-Market Drug Forecast and Market Analysis - Update

Glaucoma: Epidemiology Forecast to 2033

Macular Degeneration Drug Pipeline Analysis Report 2025